7-Ethyl-10-hydroxy-18-nor-20-desoxycamptothecin | 178949-37-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-Ethyl-10-hydroxy-18-nor-20-desoxycamptothecin
• 英文别名: 10-Ethyl-7-hydroxy-19-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
• CAS: 178949-37-6
• 化学式: C₂₁H₁₈N₂O₄
• 分子量: 362.385
• InChiKey: RXYRXRLFONFXPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-Ethyl-10-hydroxy-18-nor-20-desoxycamptothecin 在 吡啶 、 甲醇 、 双氧水 作用下， 以 二氯甲烷 为溶剂， 反应 27.0h， 生成 7-Ethyl-10-hydroxy-18-noranhydrocamptothecin
  参考文献：
  名称：

  Synthesis of 18-Noranhydrocamptothecin Analogs Which Retain Topoisomerase I Inhibitory Function

  摘要：

  The total syntheses of compounds 2 and 3 are described. Key departures from previous routes to camptothecin from these laboratories involved (i) early incorporation of C-2 oxygen (see compound 9) and (ii) recourse to a Heck vinylation for installation of a hydroxymethyl equivalent on the pyridone (see transformation 15 --> 16). The final compounds are of considerable interest in that they are the most drastically modified E ring systems which retain topoisomerase I inhibitory function.

  DOI：

  10.1021/jo00102a030
• 作为产物：
  描述：

  methyl 6-hydroxy-4-methyl-3,10-dioxo-4,6,7,8-tetrahydro-1H-pyrano[3,4-f]indolizine-5-carboxylate 在 氢溴酸 、 戴斯-马丁氧化剂 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 30.0h， 生成 7-Ethyl-10-hydroxy-18-nor-20-desoxycamptothecin
  参考文献：
  名称：

  Synthesis of 18-Noranhydrocamptothecin Analogs Which Retain Topoisomerase I Inhibitory Function

  摘要：

  The total syntheses of compounds 2 and 3 are described. Key departures from previous routes to camptothecin from these laboratories involved (i) early incorporation of C-2 oxygen (see compound 9) and (ii) recourse to a Heck vinylation for installation of a hydroxymethyl equivalent on the pyridone (see transformation 15 --> 16). The final compounds are of considerable interest in that they are the most drastically modified E ring systems which retain topoisomerase I inhibitory function.

  DOI：

  10.1021/jo00102a030

文献信息

• Polymorphic form of 7-ethyl-10[4-(1-piperidino)-1- piperidino]carbonyloxy- camptothecin and its use
  申请人：Cadila Healthcare Limited

  公开号：EP2399908A1

  公开（公告）日：2011-12-28

  The present invention relates to a novel crystalline form of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin and its use in the treatment of cancer.

  本发明涉及一种新的晶体形式的7-乙基-10-[4-(1-哌啶基)-1-哌啶基]羰氧基-喜树碱及其在癌症治疗中的应用。
• (S)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano [3',4':6,7] indolizino [1.2-b]quinoline-4,9-diyl bis([1,4'-bipiperidine]-carboxylate and its use
  申请人：Cadila Healthcare Limited

  公开号：EP2399919A1

  公开（公告）日：2011-12-28

  The present invention relates to a new impurity (compound of formula (X)) of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin hydrochloride trihydrate (CPT-11) and its use as a reference standard.

  本发明涉及一种新的杂质（化合物X的式子）：7-乙基-10-[4-(1-哌啶基)-1-哌啶基]羰氧基喜树碱盐酸盐三水合物（CPT-11），以及其作为参考标准的用途。
• Solid Form of [1,4']-Bipiperidinyl-1'-Carbonyl Chloride
  申请人：Cadila Healthcare Limited

  公开号：EP2399907A1

  公开（公告）日：2011-12-28

  The present invention relates to a process for the isolation of 1-chlorocarbonyl-4-piperidinopiperidine and novel crystalline form of 1-chlorocarbonyl-4-piperidinopiperidine.

  本发明涉及一种分离1-氯甲酰基-4-哌啶基哌啶的过程，以及1-氯甲酰基-4-哌啶基哌啶的新晶体形式。
• Synthesis of 18-Noranhydrocamptothecin Analogs Which Retain Topoisomerase I Inhibitory Function
  作者：Lawrence Snyder、Wang Shen、William G. Bornmann、Samuel J. Danishefsky

  DOI：10.1021/jo00102a030

  日期：1994.11

  The total syntheses of compounds 2 and 3 are described. Key departures from previous routes to camptothecin from these laboratories involved (i) early incorporation of C-2 oxygen (see compound 9) and (ii) recourse to a Heck vinylation for installation of a hydroxymethyl equivalent on the pyridone (see transformation 15 --> 16). The final compounds are of considerable interest in that they are the most drastically modified E ring systems which retain topoisomerase I inhibitory function.